Overview
US biopharmaceutical firm's Q1 revenue fell sharply and missed analyst expectations
Net loss widened yr/yr, driven by higher R&D expenses for internal programs
Company expanded prolactin program portfolio and initiated new clinical trial dosing
Outlook
Absci anticipates reporting preliminary ABS-201 safety and PK data in Q2 2026
Company expects interim ABS-201 proof-of-concept data in H2 2026, full data in early 2027
Absci projects cash resources will fund operations into the first half of 2028
Result Drivers
R&D SPENDING - Higher research and development expenses were mainly due to advancement of internal programs, including costs for ABS-201 preclinical and clinical development
PIPELINE EXPANSION - Company expanded prolactin program portfolio with addition of ABS-202 and initiated new clinical trial dosing cohorts
Company press release: ID:nGNXbYrX6g
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$215,000
$1.55 mln (6 Analysts)
Q1 Net Income
-$29.60 mln
Q1 Basic EPS
-$0.19
Q1 Operating Expenses
$31.06 mln
Q1 Operating Income
-$30.85 mln
Q1 Pretax Profit
-$29.58 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Absci Corp is $9.00, about 51.3% above its May 6 closing price of $5.95
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)